Is Biogen Becoming A Reasonable Target For Acquisition? Baird Says So
June 22, 2016 at 15:21 PM EDT
Baird's Brian Skorney reiterated Biogen Inc (NASDAQ: BIIB)'s Neutral rating with a $268 price target. The reiteration came after ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.